Uluslararası Konferans Bildirileri1991 Yılı 1. Kucuk O, Demirer T, Gilman-Sachs A, Westerman M.P. et al: Correlation of DNA ploidy with stage and histology in prostate cancer patients. Proceedings of the American Association for Cancer Research, Volume 32, Abs. No:160, March 1991. 1994 Yılı 2. Demirer T, Buckner C.D, Petersen F.B, Appelbaum F, Rowley S, Lilleby K, Sanders J, Chauncey T, Storb R, Benyunes MC, Fefer A, and Bensinger W.: Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells in patients with acute myelogenous leukemia (AML). "BLOOD" Vol:84, No:10, Suppl 1, pp 92a, Abstr:356, 1994. 1995 Yılı 4. Demirer T, Bensinger WI, Rowley S, Appelbaum FR, Petersen FB, Chauncey T, Fefer A, Buckner CD: Comparison of granulocyte-colony stimulating factor mobilized peripheral blood stem cells and bone marrow for autologous transplantation in patients with acute myelogenous leukemia. "BLOOD" Vol:86, No:10, Suppl 1, pp 99a, Abstr:381, 1995. 5. Demirer T, Bensinger WI, Appelbaum FR, Rowley S, Buckner CD: Autologous stem cell transplantation for patients with multiple myeloma. "BLOOD" Vol:86, No:10, Suppl 1, pp 207a, Abstr:815, 1995. 6. Chauncey TR, Gooley TA, Appelbaum FR, Demirer T, Holmberg L, Lilleby K, Rowley SD, Buckner CD: Quantitative CD34 collection does not independently predict clinical outcome after autologous PBSC transplantation. "BLOOD" Vol:86, No: 10, Suppl 1, pp 941a, Abstr: 3751, 1995. 1996 Yılı 7. Demirer T, Buckner CD, Storer B, Rowley S, Schiffman K, Bensinger WI: The effect of different chemotherapy regimens on peripheral blood stem cell mobilization yield. ASCO proceedings. Vol:15, P:345, Abstr:1007, 1996. 1997 Yılı 8. Holmberg L.A, Demirer T, Schiffman K, Rowley SD, Buckner CD, Goodman G, Maziarz R, Appelbaum FR, and Bensinger WI: High-dose busulfan, melphalan, and thiotepa (BUMELTT) followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. “BLOOD” , Vol:90, No:10, Suppl 1(part 1 of 2) abstr:1705, 1997. 1998 Yılı 9. Arat M, Üstün C, Arslan Ö, Ayyıldız E, Koç H, Beksaç M, Akan H, Gürman G, Özcan M, Demirer T, Uysal A, Konuk N, İlhan O: Correlation of CD34+ mononuclear cells and engraftment time in allogeneic peripheral blood stem cell transplantation. Boletim da Sociedade Brasileira de Hematologia a hemoterapia (VII International Congress of the World Apheresis Association-WAA), Abstract C 75, pp 176, Volume XX-Suplemento Outubro 1998, ISSN 0102-7662. 10. M. Özcan, C. Üstün, O. İlhan, M. Beksaç, E. Akçağlayan, G. Gürman, H. Akan, T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation. BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2), abstr:4405, pp 326b, 1998. 11. G. Gürman, C. Üstün, Ö. Arslan, M. Beksaç, N. Konuk, M. Arat, H. Çelebi, M. Özcan, O İlhan, T. Demirer, H. Akan, A. Uysal, H. Koç. Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignancies by using non-myeloablative conditioning regimen. BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2), abstr:4509, pp 350b, 1998. 12. C. Üstün, M. Özcan, M. Beksaç, O İlhan, M. Çakır, G. Gürman, H. Akan, T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. Clinical effects of intravenous immüne globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation. BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2), abstr:4528, pp 355b, 1998. 13. Üstün C, İdilman R, Özcan M, Akan H, Karayalçın S, Gürman G, İlhan O, Beksaç M, Uysal A, Konuk N, Demirer T, Koç H. Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers. HEPATOLOGY vol: 28, No 4, S, pp 2221, 1998. 1999 Yılı 14. Gürman G, Üstün C, Arslan Ö, Beksaç M, Konuk N, Arat M, Çelebi H, Özcan M, İlhan O, Demirer T, Akan H, Uysal A, Koç H: Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using non-myeloablative conditioning regimen. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:70, S22, 1999. 15. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H, Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: Clinical effects of intravenous immune gloguline (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:567, S171, 1999. 16. Demirer T, Arat M, Koç H, İlhan O, Çelebi H, Özcan M, Akan H, Gürman G, Uysal A: A protocol proposal comparing conventional approach with high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in patients with small cell lung cancer limited to thorax. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:625, S189, 1999. 17. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun Ş, Beksaç M, Akan H, Özcan M, Arslan Ö, Gürman G, Koç H: The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:672, S201, 1999 18. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Gürman G, Akan H, Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:688, S205, 1999 19. Arat M, Demirer T, Ilhan O, koç H, Üstün C, Çelebi H, Ayyıldız E, Tüzün A, Gürman G, Özcan M: Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY) – paclitaxel and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast cancer: Ibn-i Sina experience. 20. Arat M, Demirer T, Üstün C, Çelebi H, Tüzün A, Coşkun Ş, Ayyıldız E, İlhan O, Gürman G, Özcan M, Koç H. A phase I dose escalation study of high dose thiotepa, melphalan and carboplatin in patients with high risk breast cancer and hematologic malignancies. Proceedings of ASCO Vol:18, abstract 207, pp 56a, 1999. 21. Beksaç M, Akan H, Koç H, İlhan O, Uysal A, Özcan M, Demirer T, Konuk N et al: Comparison of allogeneic peripheral blood stem cell transplantation: A prospective randomized EBMT study. Results of Ankara University. Turk J Haematol, 16, 3 (suppl 1): abstr 40, pp 138, 1999. 22. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Arslan Ö, Gürman G, Akan H, Demirer T, et al: The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 43, pp 140, 1999. 23. Demirer T, İlhan O, Mandel NM, Arat M, Çelebi HA phase I dose escalation study of high-dose thiotepa, melphalan, and carboplatin (TMCb) followed by autologous peripheral blood stem cell (PBSC) transplantation in patients with solid tumors and hematologic malignancies. Turk J Haematol, 16, 3 (suppl 1): abstr 44, pp 140, 1999. 24. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H, İlhan O, Konuk N, Demirer T, et al: Experience of ibn-I sina hospital in allogeneic peripheral blood stem cell transplantation for standard risk leukemia patients. Turk J Haematol, 16, 3 (suppl 1): abstr 46, pp 141, 1999 25. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H, Demirer T, et al: Clinical effects of intravenous immune globuline (IVIG) treatment in patients with allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 49, pp 143, 1999 26. Gürman G, Üstün C, Arslan Ö, Beksaç M, konuk N, Arat M, Çelebi H, Özcan M, İlhan O, Demirer T et al: Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen. Turk J Haematol, 16, 3 (suppl 1): abstr 50, pp 143, 1999 27. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun HŞ, et al: The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT. Turk J Haematol, 16, 3 (suppl 1): abstr 51, pp 144, 1999 28. Arslan Ö, Arat M, İlhan O, Ayyıldız E, Üstün C, Çelebi H, Tekin M, Özcan M, Gürman G, Demirer T et al: The influence of donors peripheral blood CD34+ cells on collection and engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 52, pp 144, 1999 29. Arslan Ö, Coşkun HŞ, Akçağlayan E, Özcan M, Gürman G, Arat M, Çelebi H, Demirer T, et al: Comparison of ABO/Rh blood group incompatible and compatible patients in allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 53, pp 145, 1999 30. Arat M, Arslan Ö, Ayyıldız E, Akan H, Koç H, Özcan M, Gürman G, Demirer T et al: CD34 positive stem cell selection with isolex 300I: The first live procedure in Turkey. Turk J Haematol, 16, 3 (suppl 1): abstr 56, pp 146, 1999 31. Özcan M, Çelebi H, Gürman G, Arslan Ö, Demirer T et al: Treatment of refractory AGVHD with anti-thymocyte globulin. Turk J Haematol, 16, 3 (suppl 1): abstr 57, pp 147, 1999 32. İlhan O, Demirer T, Arat M, Arslan Ö, Dalva K, et al: Platelet engraftment after allo PBSCT: the role of CD41+ and CD42+ stem cells. Haematologica, vol:84, EHA-4 Abstr book, abstr PO-0282, pp 66, 1999. 33. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H, İlhan O, Konuk N, Demirer T et al: Experience of Ibn-I Sina Hospital in allogeneic peripheral blood stem cell transplantation for standar risk leukemia patients. Haematologica, vol:84, EHA-4 Abstr book, abstr PO-0283, pp 66, 1999. 2000 Yılı 35. Aylı M, Çelik Z, Oymak A, Fen T, Tekin K, Eser N, Demirer T. Mobilization of hematopoietic progenitor cells with paclitaxel, cyclophosphamide (CY) and recombinant human granulocyte-colony stimulating factor (rh-GCSF) in patients with lymphoid malignancies and breast cancer. The Hematology Journal, Vol 1, suppl 1, abstr 743, pp 190, 2000. 36. Aylı M, Fen T, Demirer A, Çelik Z, Oymak A, Özdel Ö, Demirer T. CD34+ PBSC mobilization with cyclophosphamide (CY), paclitaxel and recombinant human granulocyte colony stimulating factor (Rh-GCSF) in patients with lymphoid malignancies. Annals of Oncology, Vol 11, Suppl 4, 439P, 2000. 37. Demirer T, Aylı M, Demirer A et al. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), etoposide and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with hematologic malignancies and solid tumors. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5105, pp 314b, 2000. 38. Demirer T, Aylı M, Demirer A, et al. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), epirubicin and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast and ovarian cancer. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5106, pp 315b, 2000. 39. Ilhan O, Arslan Ö, Arat M, Özcan M, Gürman G, Dalva K, Beksaç M, Demirer T et al. The value of peripheral blood CD34+ cell quantitation in autologous hematopoietic stem cell apheresis. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5111, pp 316b, 2000. 40. Demirer T, Ilhan O, Aylı M, et al. Phase-II study of high-dose thiotepa, melphalan, and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5344, pp 368b, 2000. 2001 Yılı 41. Demirer T, Ilhan O, Aylı M, Arat M, Fen T et al. High-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors. Bone Marrow Transplantation, Vol:27, Suppl 1, EBMT 2001. 42. Demirer T, Ilhan O, Aylı M, et al. Cyclophosphamide (CY), etoposide (E) and granulocyte-colony stimulating factor (G-CSF) for the collection of peripheral blood stem cells. ASCO Proceedings, Abstract 67, pp 18a, Poster presentation, 2001. 43. Demirer T, Aylı M, Ilhan O, et al: Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), etoposide (E) and granulocyte-colony stimulating factor : The effect of preleukapheresis circulating (PLC) CD34 cells on the yield. The Hematology Journal, Volume-I, Suppl 1, Poster 761, 2001. 44. Demirer T, Aylı M, Günel N, et al: A randomized study of comparison of leukapheresis volumes 8 L versus 10 L. The Hematology Journal, Volume-I, Suppl 1, Abstract 768, 2001. 45. Arat M, Arslan Ö, Ayyıldız E, Çitçi A, Demirer T, Ilhan O. Stem cell mobilization with cyclophosphamide (CY) based regimen in multiple myeloma: Ibn-i Sina Experience. XIII Congress of the European Society for Haemapheresis. Rıva del Garda, Italy, Poster, page 171, 2001. 46. Arslan Ö, Arat M, Ozcan M, Gürman G, Koç H, Ahan H, Demirer T et al. Autologous peripheral blood stem cell mobilization: Ibn-i Sina Experience. XIII Congress of the European Society for Haemapheresis. Rıva del Garda, Italy, Poster, page 174, 2001. 48. Ilhan O, Arat M, Arslan O, Ozcan M, Gürman G, Demirer T, Konuk N, Uysal A, Akan H: Evaluation of Mobilization efficiency of cyclophosphamide (CY) based regimen by peripheral blood CD34+ cell quantification. XIII Congress of the European Society for Haemapheresis. Rıva del Garda, Italy, Poster, page 192, 2001. 49. Demirer T, Aylı M, Arat M, Ozcan M, Gunel N, Haznedar R, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (RhG-CSF): A randomized evaluation of different doses of RhG-CSF. Blood, Vol 98, No: 11, Poster sunusu, Poster No: 751, 2001. 50. Demirer T, Aylı M, Arat M, Gunel N, Ozcan M, Haznedar R, et al. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 L versus 10 L. Blood, Vol: 98, No:11, Abstract 5082, 2001, 2002 Yılı 51. Bengala C, Guarneri V, Ledermann J, Wandt H, Lotz J, Cure J, Rosti G, Ferrante P, Demirer T, Conte P on behalf of the Solid Tumour Working Party of the EBMT. High-dose chemotherapy with autologous hemopoietic support for advanced ovarian cancer in 1st complete remission: retrospective analysis from Solid Tumor Registry of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, Vol 29, Suppl 2, S 32, abstr 200 (Oral presentation), 2002. 52. Demirer T. The EBMT Solid Tumours Working Party (STWP) Registry: 2001 report. Bone Marrow Transplantation, Vol 29, Suppl 2, S 189, abstr 702 (Poster presentation), 2002. 53. Demirer T, Aylı M, Ozcan M,et al. Mobilization of peripheral blood stem cells with chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized evaluation of different doses of G-CSF. Bone Marrow Transplantation, Vol 29, Suppl 2, S 193, abstr 713 (Poster presentation), 2002. 54. Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant granulocyte-colony stimulating factor (G-CSF) administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, Vol 29, Suppl 2, S 197, abstr , 2002. 57. Demirer T, Aylı M, Daglı M,et al. Mobilization of peripheral blood stem cells with chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized evaluation of different doses of G-CSF. ASCO Proceedings, Vol: 21, Part 1 0f 2, Poster discussion, Abstr 1667, page 417a, 2002. 58. Aylı M, Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant granulocyte-colony stimulating factor (G-CSF) administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. ASCO Proceedings, Vol: 21, Part 1 0f 2, Poster , Abstr 1690, page 423a, 2002. 59. Kröger N, Zander AR, Ferrante P, Martinelli G, Janvier M, Moraleda J, Cellerino G, Zambelli A, Blaise D, Demirer T, Rosti G on behalf of the EBMT Working Party on Solid Tumors. Incidence of secondary myelodysplasia (sMDS) and acute leukemia (sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients. ASCO Proceedings, Vol: 21, Part 2 0f 2, Abstr 2035, page 56b, 2002. 60. Demirer T, Genc Y, Ayli M, et al. Influence of post-transplant granulocyte-colony stimulating factor (G-CSF) administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. The Hematology Journal, Vol: 3, Suppl 1, abstr: 84 (Poster presentation), pp 37, June 2002. 61. Demirer T, Ayli M, Dagli M, et al. The effect of post-transplant spironolactone administration on daily potassium requirements in patients undergoing autologous stem cell transplantation. The Hematology Journal, Vol: 3, Suppl 1, abstr: 83 (Poster presentation), pp 37, June 2002. 62. Demirer T. CD34+ cells in the field of hematopoietic stem cell transplantation. IXth International Symposium on Biomedical Science and Technology, BIOMED 2002, Abstr: I-14, pp:017. 63. Demirer T. The EBMT Solid Tumors Working Party (STWP) registry: 2001 report. 2nd International Congress on advances in Hematology-Oncology and BMT, Tehran, IRAN, September 25-29, pp:14, 2002. 64. Demirer T. High-dose chemotherapy (HDC) in the adjuvant setting in patients with high risk primary breast cancer. . 2nd International Congress on advances in Hematology-Oncology and BMT, Tehran, IRAN, September 25-29, pp:25, 2002. 65. Aylı M, Demirer T, Konuk N, et al. Influence of post-transplant recombinant human granulocyte colony stimulating factor (RhG-CSF) administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Annals of Oncology, Vol:13, Supplement 5, pp 30, 2002. 66. Demirer T, Uysal A, Ayli M, et al. High dose thiotepa, melphalan and carboplatin followed by autologous stem cell transplantation in patients with advanced breast cancer. A retrospective evaluation. Annals of Oncology, Vol: 13, Supplement 5, Poster 205, pp 57, 2002. 2003 Yılı 67. Rosti G, De Giorgio U, Papiani G, Wandt H, Siegert W, Kozak T, Bornhauser M, Kulekci A, Demirer T. High-dose chemotherapy in extragonadal germ cell tumor: first results of the EBMT registry. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S35, Oral abstract: 0272, 2003. 68. Bregni M, Peccatori J, Bernardi M, Pedrazzoli P, Siena S, Aglietta M, Slavin S, Blaise D, Demirer T, Niederwieser D, Bay JO. Allogeneic stem cell transplantation in ovarian cancer: the EBMT experience. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S36, Oral abstract: 0275, 2003. 69. Kröger N, Damon L, Zander A, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G on behalf of the EBMT Solid Tumors Working Party. Secondary acute leukemia following mitoxantronebased high-dose chemotherapy for primary breast cancer. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S193, Poster abstract: P687, 2003. 70. Demirer T, Ayli M, İlhan O, Koc H, Dagli M, Arat M, Fen T, Dincer S, Ozet G, Akan H, Uysal A. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S195, Poster abstract: P695, 2003. 71. Kröger N, Damon L, Zander A, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G on behalf of the EBMT Solid Tumors Working Party. Secondary acute leukemia following mitoxantronebased high-dose chemotherapy for primary breast cancer. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S193, Poster abstract: P687, 2003. 72. Demirer T, Ayli M, İlhan O, Koc H, Dagli M, Arat M, Fen T, Dincer S, Ozet G, Akan H, Uysal A. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S195, Poster abstract: P695, 2003. 73. Demirer T, Ledermann J, Leyvraz S, Niederwieser D, Blaise D, Aglietta M, Ueno N, Rosti G. The Status of bone marrow transplant clinical trials (Teaching lecture). European Journal of Cancer. Vol: 1, No:5, pp 14, 2003. 2004 Yılı 74. Bregni M, Barkholt L, Peccatori J, Pedrazzoli P, Remberger M, Carminati O, Ciceri F, Siena S, Demirer T, Ringden O, Niederwieser D. Graft versus tumor effect following reduced-intensity allogeneic stem cell transplantation in renal cell cancer . On behalf of the EBMT Solid Tumors Working party. BLOOD, Vol: 102, No:11, part 1, pp 198a, abstract 692 (Oral presentation), 2004.
75. Barkholt L, Bregni M, Peccatori J, Pedrazzoli P, Remberger M, Carminati O, Ciceri F, Siena J, Martino R, Sierra J, Bruness M, Lenhoff S, Corradini P, Rosti G, Demirer T, Niederwieser D, Ringden O, on behalf od EBMT Solid Tumors Working Party. Graft versus tumor effect following reduced intensity allogeneic stem cell transplantation in renal cell cancer. Bone Marrow Transplantation, Vol:33, Suppl 1, abstract 97, S4, 2004, (Oral Presentation).
76. Rosti G, Papiani G, Wandt H, Leyvraz S, Demirer T, Giorgi U De on behalf of EBMT Solid Tumors Working Party. Early high dose chemotherapy for adult patients with extragonadal non-seminomatouse germ cell tumors of the mediastinum and retroperitoneum. Bone Marrow Transplantation, Vol:33, Suppl 1, abstract 265, S39, 2004, (Oral Presentation).
77. Giorgi U De, Rosti G, Slavin S, Yaniv I, Harousseau JL, Tobler A, Ladenstein R, Demirer T, Dini G on behalf of the Solid Tumors and Paediatric Diseases Working Parties. Long-term follow up after high-dose chemotherapy for paediatric patients with extragonadal germ cell tumors. Bone Marrow Transplantation, Vol:33, Suppl 1, abstract 268, S40, 2004, (Oral Presentation).
78. Demirer T, Soydan E, Fen T et al. High-dose thiotepa, melphalan, and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma- a retrospective evaluation. . Bone Marrow Transplantation, Vol:33, Suppl 1, abstract P904, S250, 2004.
79. O. Ilhan, P. Topcuoglu, M. Arat, E. Soydan, S.K. Toprak, M.K. Yuksel, C. Ustün, H. Celebi, I. Dilek, O. Arslan, M. Ozcan, G. Gurman, T. Demirer et all . Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989 - 2004) Bone Marrow Transplant 2005; 35 (Suppl. 2): S222
80. Bregni M, peccatori J, Barkholt L, Ringden O, Pedrazzoli P, Martino R, Lenhoff S, Corradini P, Demirer T, Niederwieser D. Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMt Solid Tumors Working Party. ASCO Proceedings, Vol: 22, No: 14S,, Abstr 6666, page 599s, 2004.
81. Giorgi U. De, Demirer T, Wandt H, et al. Second line high-dose chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the experience of the European Group for Blood and Marrow Transplantation (EBMT). Annals of Oncology, Vol: 15, Suppl:3, iii 121, abstract (Poster) 452P, 2004.
2005 Yılı 82. Bay JO, Durando X, Linassier C, Biron P, Kwiatkowski F, Verelle P, Rosti G, Demirer T, on behalf of the Solid Tumors Working party. High dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: An EBMT retrospective analysis of 218 patients. Bone Marrow Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation) 0272, S53, 2005,
83. Grosso F, Corradini P, Carrabba M, Castagna L, Pedrazzoli P, Gobel U, Demirer T, Niederwieser D, on behalf of Solid Tumors Working party. Allogeneic stem cell transplantation in advanced soft tissue sarcomas: a retrospective analysis on the EBMT STWP. Bone Marrow Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation) 0272, S53, 2005,
84. İlhan O, Topcuoglu P, Arat M, Soydan E, Özcan M, Gürman G, Demirer T, Akan H et al. Allogeneic hematopoietic stem cell transplantation in acute myeloblastic leukemia.: İbn-i Sina experience (1989-2004). Bone Marrow Transplantation, Vol: 35, Suppl 2, Abst (Oral Presentation) 0272, S53, 2005,
85. Pervin Topçuoğlu, Taner Demirer et all. When to start G-CSF after mobilization regimen? Any impact on stem cell collection efficiency (abstract 141, sayfa: 231). The 15th Congress of the ESFH (Transfusion and Apheresis Science, 2005; 33(2)
86. M Özcan, M K Yüksel, P Topçuoğlu, E A Soydan, S K Toprak, M Beksaç, A Uysal, H Akan, T Demirer, et all. Addition of ANTI-CD20 to high dose chemotherapy with autologous peripheral blood stem cell transplantation prolong disease free survivalin non-Hodgkin’s lymphomas: A Matched-controlled analysis (Abstract: 573 Poster: 480). XXX. World Congress of the International Society of Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)
87. P Topçuoğlu, F EKiz, E A Soydan, M K Yüksel, S K Toprak, M Özcan, Ö Arslan, G Gürman, T Demirer, et all. How to calculate the quantity of CD34(+) cells infused? A single center cohort study based on actual, ideal or adjusted ideal body body weight (Abstract: 668 Poster: 575). XXX. World Congress of the International Society of Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)
88. O İlhan, P Topçuoğlu, M Arat, E A Soydan, M K Yüksel, S K Toprak, Ö Arslan, M Özcan, G Gürman, T Demirer et all. Allogeneic hematopoietic cell transplantation in acute myeloblastic leukemia: Ankara University Experience (Abstract: 672 Poster: 579). XXX. World Congress of the International Society of Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)
89. P Topçuoğlu, Ö T İyidir, K Dalva, E A Soydan, M K Yüksel, S K Toprak, H Koç, A Uysal, M. Beksaç, M Özcan, M Arat, T Demirer et all. When to start G-CSF after mobilization regimen? Any impact on stem cell collection efficiency (Abstract: 759 Poster: 666). XXX. World Congress of the International Society of Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)
90. Gökhan Kabaçam, Mutlu Arat, Ender Soydan, Klara Dalva, Erol Ayyıldız, Günhan Gürman, Taner Demirer, Hamdi Akan, Meral Beksaç, Osman İlhan. Factors effecting peripheral stem cell collection in multiple myeloma patients.(poster 612), S:127. Haematologica 2005, suppl 10th International Myeloma Workshop, Sydney, April 10-14, 2005
91. O. Ilhan, P. Topcuoglu, M. Arat, E. Soydan, S.K. Toprak, M.K. Yuksel, C. Ustün, H. Celebi, I.Dilek, O. Arslan, M. Ozcan, G. Gurman, T. Demirer, H. Akan, M. Beksac, A. Uysal, N. Konuk, H. Koc. Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989 - 2004) 31st Annual Meeting of the European Group for Blood and Marrow Transplantation 20-23 March 2005
92. P. Topçuoğlu, ÖT. İyidir, K. Dalva, EA. Soydan, MK. Yüksel, SK. Toprak, H Koç, VA Uysal, M. Beksaç, M. Özcan, Ö. Arslan, N. Konuk, M. Arat, T. Demirer, O. İlhan. When to start G-CSF after mobilization regimen? Any impact on stem cell collection efficiency. Turk J Haematol 2005; 22: 312 (P 666)
2006 Yılı
93. Aglietta M, Barkholt L, Niederwieser D, Ringden O, Demirer T. Allogeneic hematopoietic cell transplantation after reduced intense conditioning as adoptive cell therapy in resistant metastatic colorectal carcinoma. The European Experience. Journal of Clinical Oncology, Vol: 24, No: 18s, Part I, 2006.
94. Arat M, Cengiz G, Ayyıldız E, Topçuoğlu P, Arslan Ö, Özcan M, Gürman G, Dalva K, Beksaç M, Demirer T, et all . Retrospective validation of an apheresis cycle calculator of autologous PBSC collection in myeloma and malignant lymphoma patients. Abstract Book, ESFH 2006 Meeting, 20-21 June 2006, Umea, Sweden (Oral Presentation).
95. Arat M, Soydan E, Cengiz G, Ayyildiz E, Topcuoglu P, Arslan O, Ozcan M, Gurman G, Dalva K, Beksac M, Demirer T, et all. Retrospective validation of an apheresis cycle calculator on autologous PBSC collection in myeloma and malignant lymphoma patients. CYTOTHERAPY 8: Suppl. 1, 2006.
2007 Yılı 96. Aglietta M, Barkholt L, Caravelli D, Omazig B, Ciccone G, Niederwieser D, Ringden O, Demirer T on behalf of EBMT STWP. Allogeneic hematopoietic cell transplantation after reduced intense conditioning as adoptive cell therapy in resistant metastatic colorectal carcinoma. The European Experience. 24, No 18S Part I of II, Poster 3596, J Clin Oncol, 2007.
97. Arat M, Gurman G, Demirer T, Beksaç M et al. Time intervals preceeding autologous stem cell transplantation in multiple myeloma patients : a single center intent to transplant analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract R1172, S322, 2007.
98. Serbest E, Ozcan M, Arslan O, Demirer T, Beksac M, Arat M et al. The impact of disparity in short tandem repeats analysis on the outcome of allogeneic haematopoietic cell transplantation from HLA identical sibling donors. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P799 , S197-198, 2007.
99. Soydan E, Arslan O, Ozcan M, Demirer T, Arat M et al. The impact of histopathological subtype of cutaneous chronic GVHD on alloHSCT outcome: lichenoid versus sclerodermoid. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P549, S106-107, 2007.
100. Ugur Bİlgin A, Soydan E, Akan H, Gurman G, Demirer T, Arat M et al. The impact of pretransplant imatinib use in allogeneic HSCT for CML: a single center comparative analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P444, S68-69, 2007,
101. P. Topcuoglu, S. Civriz Bozdağ, B. Ceydilek, MK Yüksel, ŞM Bakanay, Ö. Arslan, T Demirer, et all. EMA as a salvage regimen in patiens with refractory/relapse AML: A single center experience. Turk J Hematol 2007; 1 (suppl 1): 110-111
102. E. Serbest, P. Topcuoglu, K. Dalva, E.A. Soydan, O. Arslan, M. Ozcan, T. Demirer, et all. The impact of disparity in short tandem repeats analysis on the outcome of allogeneic haematopoietic cell transplantation from HLA-identical sibling donors. Haematologica, the Hematology Journal 2007; 92 (suppl 1): 517
2008 Yılı
103. Bay J.O, Tabrizi R, Blaise D, Viens P, Ehninger G, Slavin S, Rosti G, Demirer T , Bregni M. Allogeneic stem cell transplantation in ovarian cancer. The EBMT experience. Bone Marrow Transplantation, S 310, p 998, 2008.
104. Bertuzz. A, Tienghi A, Pedrazzoli P, Castagna L, Demirer T, Bregni M. Long term outcome in adult Ewing’s sarcoma patients treated with high-dose chemotherapy : results of a retrospective analysis of the EBMT. Bone Marrow Transplantation, S 311, p 999, 2008.
105. Demirer T, Ueno N, Bregni M, Berry D, on behalf of the MDACC-EBMT Meta-analysis Group. High-dose chemotherapy with a stem cell support-versus-standard dose chemotherapy: meta-analysis of individual patient data from 15 randomised breast cancer trial. Bone Marrow Transplantation, S 311, p 999, 2008.
106. DA Berry, NT Ueno, MM Johnson, X Lei, D Smith, J Caputo, L Yancey, M Bregni, T Demirer, on behalf of MDACC-EBMT Meta-analysis Group. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. 31st Annual San Antonio Breast Cancer Symposium. Abstr No: 551494, 2008. 2009 Yılı 107. Demirer T, Ueno N, Johnson M, Bregni M, Berry DA, on behalf of the EBMT-MDACC Meta-analysis group. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomised metastatic breast cancer trials. Oral Presentation. Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.
108. Civriz BS, Topcuoglu P, Bakanay s, Arat M, Beksac M, Arslan Ö, Demirer T, Gurman G, Ozcan M. The effect of rituximab in first line therapy results of autologous hematopoietic stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients. Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009. 
|
||||||
|
||||||
